PDR 001

Drug Profile

PDR 001

Alternative Names: PD-1 inhibitor - Novartis Oncology; PDR001

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Nasopharyngeal cancer; Neuroendocrine tumours
  • Phase I/II Solid tumours
  • Phase I Cancer; Lymphoma
  • Phase Unknown Hepatocellular carcinoma

Most Recent Events

  • 20 Mar 2017 Novartis plans a phase I trial for Colorectal cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) (NCT03081494)
  • 03 Mar 2017 Novartis Pharmaceuticals plans a phase I trial (Combination therapy, Refractory metastatic disease) for Acute Myeloid Leukemia and Myelodysplastic Syndrome in USA (NCT03066648)
  • 02 Mar 2017 Novartis Pharmaceuticals plans a phase I trial (Combination therapy, Late-stage disease) for Non-small cell lung cancer in USA (NCT03064854)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top